---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Vagus nerve stimulation and other neuromodulation"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Vagus nerve stimulation and other neuromodulation. Topics: CANMAT guideline: VNS third-line, DBS investigational; VA/DoD guideline: against VNS and DBS outside research; NICE interventional procedures guidance on implanted VNS; Medicare coverage of VNS limited to coverage with evidence development; 5 further topics. 9 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description/vagus-nerve-stimulation-and-other-neuromodulation"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Vagus nerve stimulation and other neuromodulation

<a id="heading-2.2.2.1.8"></a>

## 2.2.2.1.8 Vagus Nerve Stimulation and Other Neuromodulation

<a id="topic-2.2.2.1.8-1"></a>

### CANMAT guideline: VNS third-line, DBS investigational

> “To date, there are very few RCTs involving VNS, and these studies have failed to demonstrate the efficacy of VNS compared to sham control conditions in the short term.”
> “VNS is generally safe and well tolerated, with the most common side effects involving pain related to device implantation, voice hoarseness or alteration (due to intermittent stimulation of the larynx), coughing, headache, sore throat, and neck pain.”
> “Currently, VNS is the only surgical neuromodulation treatment approved for TRD by regulatory agencies and is recommended as a third-line option”
> “DBS and MST are currently considered investigational due to limited available evidence.”

Source: [Lam et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11351064/)

<a id="topic-2.2.2.1.8-2"></a>

### VA/DoD guideline: against VNS and DBS outside research

> “For patients with MDD, we suggest against using vagus nerve stimulation outside of a research setting.”
> “(Weak against | Reviewed, Amended)”
> “Evidence indicates a greater than 5% chance of significant adverse events for patients who have been implanted with VNS.”
> “For patients with MDD, we recommend against using deep brain stimulation outside of a research setting.”
> “(Strong against | Reviewed, Not changed)”

Source: [VA/DoD (2022)](https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf)

<a id="topic-2.2.2.1.8-3"></a>

### NICE interventional procedures guidance on implanted VNS

> “Evidence on the safety of implanted vagus nerve stimulation for treatment-resistant depression raises no major safety concerns, but there are frequent, well-recognised side effects.”
> “Evidence on its efficacy is limited in quality.”
> “Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.”

Source: [NICE (2020)](https://www.nice.org.uk/guidance/htg551/chapter/1-Recommendations)

<a id="topic-2.2.2.1.8-4"></a>

### Medicare coverage of VNS limited to coverage with evidence development

> “Effective for services performed on or after February 15, 2019, the Centers for Medicare & Medicaid Services (CMS) will cover FDA-approved VNS devices for treatment resistant depression (TRD) through Coverage with Evidence Development (CED) when offered in a CMS-approved, double-blind, randomized, placebo-controlled trial with a follow-up duration of at least one year”
> “VNS is non-covered for the treatment of TRD when furnished outside of a CMS-approved CED study.”
> “All other indications of VNS for the treatment of depression are nationally non-covered.”

Source: [CMS vagus nerve stimulation national coverage determination (2019)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=230)

<a id="topic-2.2.2.1.8-5"></a>

### RECOVER: 12-month sham-controlled trial

> “This 12-month, multicenter, double-blind, sham-controlled trial included 493 adults with marked treatment-resistant major depression who were randomized to active or no-stimulation sham VNS for 12 months.”
> “Percent time in MADRS response did not distinguish active from sham VNS.”
> “Active VNS exceeded sham VNS in rate of dyspnea (P = 0.035), a known side effect of VNS.”

Source: [Conway et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39706521/)

<a id="topic-2.2.2.1.8-6"></a>

### RECOVER: quality of life and function

> “Active VNS was superior to sham in mean change in scores from baseline in the Mini-Q-LES-Q (P = 0.050) and WPAI item 6 (health condition's effect on regular activities [P = 0.050]) used as continuous variables, with a similar trend for Q-LES-Q (P = 0.061).”

Source: [Rush et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39701918/)

<a id="topic-2.2.2.1.8-7"></a>

### RECOVER: durability of benefit over 24 months

> “Prospective, open-label, single-arm, long-term extension study (RECOVER) conducted from September 2019 to April 2025.”
> “Depressive symptom, daily function, and QoL benefits obtained after 12 months of adjunctive VNS were sustained in about 80% of participants continuing VNS.”
> “It did not demonstrate that VNS was necessary in achieving this sustained benefit.”
> “Conducting the study was also supported by the Centers for Medicare & Medicaid Services.”

Source: [Conway et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12799215/)

<a id="topic-2.2.2.1.8-8"></a>

### Five-year registry: adjunctive VNS compared with treatment as usual

> “This 5-year, prospective, open-label, nonrandomized, observational registry study was conducted at 61 U.S. sites and included 795 patients”
> “The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%).”

Source: [Aaronson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28359201/)

<a id="topic-2.2.2.1.8-9"></a>

### Deep brain stimulation of the ventral anterior limb of the internal capsule

> “Following the optimization phase, which lasted 51.6 (22.0) weeks, 10 patients (40%) were classified as responders and 15 individuals (60%) as nonresponders.”
> “During active DBS, patients scored significantly lower on the HAM-D-17 scale (13.6 [95% CI, 9.8-17.4]) than during sham DBS (23.1 [95% CI, 20.6-25.6]) (P < .001).”
> “Serious adverse events included severe nausea during surgery (1 patient), suicide attempt (4 patients), and suicidal ideation (2 patients).”

Source: [Bergfeld et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27049915/)

Additional sources: [Conway et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42642808/); [McAllister-Williams et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008595/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
